Inventive steps: the <scp>CRISPR</scp> patent dispute and scientific progress

Sherkow, Jacob S.

doi:10.15252/embr.201744418

Cited by 17 publications

(9 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The first is the PTAB's own no interference-in-fact decision that said in no uncertain terms that UC did not sufficiently describe or enable eukaryotic work in its patent application. Again, there are many reasons to doubt this from a scientific perspective, as I wrote earlier, 6 but it is likely true as a matter of patent law. The second document is Virginijus Šikšnys's patent, disclosing ribonucleic CRISPR-Cas9 gene-editing complexes that also issued during that time (see Table 1).…”

Section: What Is the Status Of Uc's Patent Application?mentioning

confidence: 97%

The CRISPR-Cas9 Patent Appeal: Where Do We Go From Here?

Sherkow

2018

The CRISPR Journal

View full text Add to dashboard Cite

An appellate court in the United States affirmed the Patent Office's finding that the Broad Institute's patents covering eukaryotic applications of CRISPR-Cas9 was separately patentable over the University of California's (UC) earlier patent application. This does not bode well for future negotiations between UC and the Broad Institute, even as nuclease technology continues to eclipse the original dispute. This perspective explores the appellate decision, where UC goes from here, and what this all means for scientists in the future.

show abstract

Section: What Is the Status Of Uc's Patent Application?mentioning

confidence: 97%

The CRISPR-Cas9 Patent Appeal: Where Do We Go From Here?

Sherkow

2018

The CRISPR Journal

View full text Add to dashboard Cite

show abstract

“…In the United States a decisive aspect of patent evaluations is 'nonobviousnes' while the European Patent Office works with the concept of 'inventive step'. 51 Notably, the European Patent Office adopts a 'problem and solution' approach to assessing inventive steps, requiring technical features and technical problems to be established.…”

Section: The Borders Of Patentability and The Principle Of Transparencymentioning

confidence: 99%

Patent power in biomedical innovation: Technology governance in biomodifying technologies

Bicudo

Morrison

et al. 2022

World Intellectual Property

View full text Add to dashboard Cite

Biomedical innovation is often rewarded by exclusive proprietary rights such as patents. In the case of gene editing, induced pluripotent stem cells, and three‐dimensional (3D) bioprinting (here described as biomodifying technologies), the limitations of the patent system come into stark relief, generating both technical and political doubts. Generally, political and technological limitations are supposed to be solved with so‐called good governance, based on some principles. We focus on three of such governance principles (participation, accountability, and transparency) to show how they have been weakened, instead of strengthened, by the current patent system. We demonstrate that although patent applications are submitted by both public and private players, the latter have imposed a growing dominance in gene editing, induced pluripotent stem cells, and 3D bioprinting, disseminating their aggressive and exclusive strategies. As a consequence, a logic of experimentality tends to prevail where the three fundamental governance principles fail to be enacted.

show abstract

“…La patente de la invención es disputada en Estados Unidos por la Universidad de California y el Broad Institute, de las universidades de Harvard y MIT, representada la primera por Jennifer Doudna y el segundo por Feng Zhang y George Church, en un conflicto legal aun inconcluso (2,5,6).…”

Section: ¿Qué Es Crispr?unclassified

“…"With the ability to guide plants down different paths of cultivation, or to explore what would happen if our ancestors had picked different crops. CRISPR has turned speculation into reality -just in time for a future that will have more mouths to feed than ever before" 6. En China se ha creado el salmón del Atlántico AquAdvantage, que puede lograr el tamaño necesario para ser comercializado en tiempo dos veces más rápido que el salmón ordinario, además de consumir menos alimentos y criarse más cerca de las ciudades, reduciendo costos 7.…”

unclassified

El Derecho ante la técnica de edición genética CRISPR

Krenz

2019

Acta bioeth.

View full text Add to dashboard Cite

Resumen: La técnica de edición genética CRISPR constituye uno de los avances recientes más extraordinarios en materia de biotecnología, de alcances insospechados. En ese contexto, resulta fundamental analizar sus repercusiones en el ámbito de los derechos humanos, toda vez que, así como puede propiciar avances extraordinarios para su mejor desarrollo, puede también generar nuevas amenazas.

show abstract

Inventive steps: the CRISPR patent dispute and scientific progress

Abstract: Inventions in scientific research and inventions under patent law do not necessarily mean the same—in particular in molecular biology.

Cited by 17 publications

References 4 publications

The CRISPR-Cas9 Patent Appeal: Where Do We Go From Here?

The CRISPR-Cas9 Patent Appeal: Where Do We Go From Here?

Patent power in biomedical innovation: Technology governance in biomodifying technologies

El Derecho ante la técnica de edición genética CRISPR

Contact Info

Product

Resources

About